Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.7499 USD | -1.04% | -6.16% | +30.92% |
01:42pm | B. Riley Raises Price Target on Vaxart to $2.50 From $2, Maintains Buy Rating | MT |
01:40pm | Vaxart Receives $453 Million for Phase 2b Trial of Covid-19 Oral Pill Vaccine Candidate | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+30.92% | 133M | |
+17.73% | 124B | |
+16.88% | 111B | |
-9.04% | 23.17B | |
+5.47% | 22.94B | |
-38.15% | 17.42B | |
-7.75% | 17.42B | |
-14.64% | 16.9B | |
+3.42% | 13.71B | |
+29.63% | 11.82B |
- Stock Market
- Equities
- VXRT Stock
- News Vaxart, Inc.
- Cantor Fitzgerald Adjusts Price Target on Vaxart to $4 From $6, Maintains Overweight Rating